Alnylam Pharmaceuticals ALNY Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's operating cash flow?
- Alnylam Pharmaceuticals (ALNY) reported operating cash flow of $70.5M in Q1 2026.
- How has Alnylam Pharmaceuticals's operating cash flow changed year-over-year?
- Alnylam Pharmaceuticals's operating cash flow increased by 158.6% year-over-year, from -$120.31M to $70.5M.
- What is the long-term trend for Alnylam Pharmaceuticals's operating cash flow?
- Over 3 years (2021 to 2025), Alnylam Pharmaceuticals's operating cash flow has grown at a -6.5% compound annual growth rate (CAGR), from -$641.69M to $524.08M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.